Indication: Breast Cancer
A Phase III, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Ne
Drug Study
Principal Investigator: Laila Agrawal, M.D.Norton Cancer Institute
Sponsor: Novartis Pharmaceuticals Corp
Learn more at ClinicalTrials.gov
Email for more information: Breast-NCIResearch@nortonhealthcare.org
